BH3 mimetics to improve cancer therapy; mechanisms and examples

被引：111

作者：

Zhang, Lin ^{[1
,2
]}

Ming, Lihua ^{[1
,2
]}

Yu, Han ^{[1
,2
]}

机构：

[1] Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Sch Med,Dept Pharmacol, Pittsburgh, PA 15213 USA

[2] Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Sch Med,Dept Pathol, Pittsburgh, PA 15213 USA

来源：

DRUG RESISTANCE UPDATES | 2007年 / 10卷 / 06期

关键词：

apoptosis; cancer; drug resistance; BH3; mimetic; ABT-737;

D O I：

10.1016/j.drup.2007.08.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tumor cell survival is highly dependent on the expression of certain pro-survival Bcl-2 family proteins. An attractive therapeutic approach is to inhibit these proteins using agents that mimic the Bcl-2 homology 3 (BH3) domains of the proapoptotic Bcl-2 family members, which neutralize these proteins by binding to their surface hydrophobic grooves. A number of BH3 mimetic peptides and small molecules have been described, a few of which have advanced into clinical trials. Recent studies have highlighted ABT-737, a bona fide BH3 mimetic and potent inhibitor of antiapoptotic Bcl-2 family members, as a promising anticancer agent. This review summarizes recent advances in understanding the mechanisms of action of BH3 domains and several classes of BH3 mimetics, as well as the prospects of using these agents to improve cancer therapy. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：207 / 217

页数：11

共 115 条

[1] The Bcl-2 apoptotic switch in cancer development and therapy [J].

Adams, J. M. ;

Cory, S. .

ONCOGENE, 2007, 26 (09) :1324-1337

[2]

Amundson SA, 2000, CANCER RES, V60, P6101

[3] Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor [J].

An, J ;

Chen, YM ;

Huang, ZW .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (18) :19133-19140

[4] Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor [J].

An, J. ;

Chervin, A. S. ;

Nie, A. ;

Ducoff, H. S. ;

Huang, Z. .

ONCOGENE, 2007, 26 (05) :652-661

[5] Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: Towards personalized medicine [J].

Anderson, Judy E. ;

Hansen, Lise Lotte ;

Mooren, Frank C. ;

Post, Markus ;

Hug, Hubert ;

Zuse, Anne ;

Los, Marek .

DRUG RESISTANCE UPDATES, 2006, 9 (4-5) :198-210

[6] Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs [J].

Baell, JB ;

Huang, DCS .

BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) :851-863

[7] Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells:: role of wild-type p53 and Bcl-XL [J].

Bauer, JA ;

Trask, DK ;

Kumar, B ;

Los, G ;

Castro, J ;

Lee, JSJ ;

Chen, JY ;

Wang, SM ;

Bradford, CR ;

Carey, TE .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (07) :1096-1104

[8] Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL [J].

Becattini, B ;

Kitada, S ;

Leone, M ;

Monosov, E ;

Chandler, S ;

Zhai, DY ;

Kipps, TJ ;

Reed, JC ;

Pellecchia, M .

CHEMISTRY & BIOLOGY, 2004, 11 (03) :389-395

[9] Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide [J].

Bernal, Federico ;

Tyler, Andrew F. ;

Korsmeyer, Stanley J. ;

Walensky, Loren D. ;

Verdine, Gregory L. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (09) :2456-+

[10] Studies leading to potent, dual inhibitors of bcl-2 and Bcl-xL [J].

Bruncko, Milan ;

Oost, Thorsten K. ;

Belli, Barbara A. ;

Ding, Hong ;

Joseph, Mary K. ;

Kunzer, Aaron ;

Martineau, Darlene ;

McClellan, William J. ;

Mitten, Michael ;

ng, Shi-Chu Ng ;

Nimmer, Paul M. ;

Oltersdorf, Tilman ;

Park, Cheol-Min ;

Petros, Andrew M. ;

Shoemaker, Alexander R. ;

Song, Xiaohong ;

Wang, Xilu ;

Wendt, Michael D. ;

Zhang, Haichao ;

Fesik, Stephen W. ;

Rosenberg, Saul H. ;

Elmore, Steven W. .

JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) :641-662

← 1 2 3 4 5 6 7 8 9 10 →